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Abstract: Supplementation of progesterone in the luteal phase and continuance of progesterone 
therapy during the first trimester has been found in several studies to have benefits in promoting 
fertility, preventing miscarriages and even preventing pre-term labor. Though it can be administered 
orally, intramuscularly or even sublingually, a very effective route with fewer side effects can be 
achieved by an intravaginal route. The first vaginal preparations were not made commercially but 
were compounded by pharmacies. This had the disadvantage of lack of control by the Food and 
Drug Administration (FDA) ensuring efficacy of the preparations. Furthermore there was a lack 
of precise dosing leading to batch to batch variation. The first commercially approved vaginal 
progesterone preparation in the United States was a vaginal gel which has proven very effective. 
The main side effect was accumulation of a buildup of the vaginal gel sometimes leading to 
irritation. Natural micronized progesterone for vaginal administration with the brand name of 
Utrogestan A® had been approved even before the gel in certain European countries. Endometrin® 
vaginal tablets are the newest natural progesterone approved by the FDA. Comparisons to the 
vaginal gel and to intramuscular progesterone have shown similar efficacy especially in studies 
following controlled ovarian hyperstimulation and oocyte egg retrieval and embryo transfer. 
Larger studies are needed to compare side effects.
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The importance of progesterone for health 
and fertility
Normal ovulating women secrete progesterone during the second half of the menstrual 
cycle by the corpus luteum which forms from the dominant follicle from which the 
oocyte has been released. Since the corpus luteum dominates this part of the cycle it is 
known as the luteal phase. Progesterone induces a secretory transformation of the uterine 
glands, increases vascularity of the endometrial lining, and stabilizes the endometrium in 
preparation for embryo implantation. Progesterone is also important in interacting with 
progesterone receptors on gamma/delta T cells leading to the expression of a protein 
that interferes with natural killer cells especially at the maternal fetal interphase.1–3
For those women not trying to conceive the absence or diminished secretion of 
progesterone may lead to endometrial hyperplasia or endometrial cancer or merely 
abnormal uterine bleeding. Treatment with synthetic progestins, eg, oral medroxy-
progesterone acetate, will effectively provide protection. However, because of some 
fear linking this oral compound with breast cancer, some women may prefer natural 
progesterone.Therapeutics and Clinical Risk Management 2009:5 404
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There are some women trying to conceive naturally who 
may fail to do so because of a deficiency in progesterone even 
in those women who appear to be ovulating.4–6 Treatment 
with compounded vaginal suppositories has been found to 
greatly improve pregnancy rates in women who have a luteal 
phase defect despite having regular menses and attaining 
a mature follicle.6,7 In fact, in women with out-of-phase 
endometrial biopsies the presence of “pure” luteal phase 
defects, in which the dominant follicle attains an 18–24 mm 
dimension associated with a serum estradiol 200 pg/mL, 
occurs in a majority of these women with regular menses.6 
In this circumstance vaginal progesterone suppositories were 
found to achieve superior pregnancy rates compared to the 
more commonly used follicle maturing drugs, eg, clomiphene 
citrate or gonadotropins.6,8
In addition, luteal phase and first trimester support with 
extra vaginal progesterone suppositories were found useful 
(at least by this author) to reduce miscarriage rates in the 
minority of women with regular menses and luteal phase 
deficiency who seem to require follicle maturing drugs and in 
completely anovulatory women requiring either clomiphene 
citrate or gonadotropins for follicular maturation.6,9
Vaginal progesterone suppositories have been demon-
strated to lower miscarriage rates even in those women not 
taking follicle maturing drugs.10,11 Some of its benefits in 
reducing miscarriage risk may be through the stimulation 
of immunomodulatory proteins that inhibit natural killer 
cell cytolytic activity and cause a shift from TH1 to TH2 
cytokines.12,13 The use of vaginal progesterone during the 
first trimester has even been associated with reducing the 
risk of preterm deliveries.14
Assisted reproductive technology 
and progesterone supplementation
The one area of assisted reproductive technology where there 
is no question about the need for supplemental progesterone 
is in women with ovarian failure who become donor oocyte 
recipients. These women need to achieve normal endo-
metrial development through the artificial use of estrogen 
followed by progesterone.15,16 Though one could transfer 
frozen-thawed embryos in the luteal phase of natural cycles 
or ovulatory cycles induced by follicle maturing drugs in 
women with normal ovarian function, most in vitro fertiliza-
tion centers use the artificial estrogen progesterone regimen 
described for donor oocyte recipients for women having 
frozen embryo transfer(s).
When using controlled ovarian hyperstimulation (COH) 
for purposes of in vitro fertilization-embryo transfer 
(IVF-ET) most add supplemental progesterone in the luteal 
phase. Some do so because they believe that the use of 
gonadotropin releasing hormone agonists or antagonists used 
to prevent a premature LH surge may have adverse effects 
on corpus luteal function.17,18 There are others who think 
that the adverse effect on luteal function is related to the 
high levels of serum estradiol and progesterone generated by 
multiple corpora lutea19,20 Two meta-analyses of luteal phase 
support for IVF-ET cycles both found higher live delivery 
rates with supplement progesterone compared to placebo.21,22 
Progesterone seems to be as effective as supplemental hCG 
injection but with a much lower risk of the ovarian hyper-
stimulation syndrome.21
Various routes of administering 
natural progesterone
One way of administering progesterone is by intramuscular 
(IM) injection. It is rapidly absorbed and produces measur-
able serum levels within 2 to 8 hours. It has a slow clearance 
when administered in an oil vehicle.23 However IM proges-
terone in oil can be associated with a lot of side effects. It is 
not unusual for women to develop an allergy to the peanut 
oil vehicle. Sometimes the progesterone is suspended then 
in olive oil and sometimes in ethyl oleate. However other 
complications including sterile abscesses, bleeding into 
the muscle and pain at the injection site have occurred. 
There have even been reported cases of acute eosinophilic 
pneumonia.24,25 Furthermore the use of IM progesterone 
requires the aid of another person for administration.
Parenteral IM progesterone has been used for treating 
infertility and miscarriages for over 45 years.4 Compounded 
progesterone vaginal suppositories have been used for 
over 20 years.4,6,7,26–27 One of the disadvantages of vaginal 
progesterone suppositories compounded by pharmacies is 
that there is no control on batch to batch variations with no 
governing agency watching for quality control. Furthermore 
the suppositories result in a significant vaginal build up 
causing vaginal irritation.28 They leak at room temperature 
and thus are messy and may lead to yeast infections.28 One 
can reduce the irritation from these vaginal suppositories by 
adding vitamin E to the suppository.
In order to improve the efficacy and reduce side effects 
of  vaginal progesterone there have been attempts at commer-
cial development of vaginal progesterone. These US Food 
and Drug Administration (FDA) approved preparations will 
be discussed subsequently.
There has been commercial development of progesterone 
which can be administered orally. Oral progesterone in Therapeutics and Clinical Risk Management 2009:5 405
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100 and 200 mg tablets has been marketed under the brand 
same Prometrium® (Solvay Pharmaceuticals Inc., Marietta, 
GA, USA). However it is rendered mostly ineffective by the 
rapid metabolism that occurs by the rapid first pass effect 
in the liver.29 Thus though the drug produces good serum 
levels of progesterone the concentration is not very high in 
the endometrium where it counts.30 Thus oral progesterone 
is considered much less effective than IM or vaginal proges-
terone.29,30 Furthermore the metabolites of oral progesterone 
can cause significant side effects such as lightheadedness, 
vertigo, drowsiness, and gastric discomfort.
Another oral progesterone that has been used in Europe for 
IVF-ET cycles is called dydrogesterone (Duphaston®; Solvay 
Pharmaceuticals, The Netherlands).31 Its efficacy and side 
effects compared to Prometrium® are not known by this author 
because of his lack of experience with this particular drug.
Vaginal progesterone preparations 
approved by the FDA
Progesterone gel – Crinone®
Vaginal progesterone achieves lower serum levels but 
higher progesterone levels in the endometrial tissue than 
IM progesterone.32,33 Crinone® (Columbia Laboratories Inc., 
Livingston, NJ, USA) vaginal gel was the first progesterone 
preparation in the US including oral or IM preparations 
approved for IVF-ET. It adheres very effectively to the 
vagina. Thus a 90 mg one time daily insertion may be equal 
to 400 to 600 mg compounded vaginal suppositories. This 
adhesiveness leads to one of the main side effects of Crinone® 
vaginal gel, which is an accumulation of a significant build-up 
of the vaginal gel leading sometimes to irritation.
FDA-approved vaginal 
progesterone tablets
The main purpose of this manuscript is to review all information 
available concerning the newest FDA approved vaginal 
progesterone Endometrin® vaginal tablets. To do so I did a 
Medline search from 2000 until November, 2008 and including 
searches of 10 journals dealing with reproductive endocrinology 
and infertility. Furthermore to include the latest information 
I included presentations from the 2008 American Society for 
Reproductive Medicine meeting which I attended.
Endometrin® (Ferring Pharmaceuticals, Parsippany, NJ, 
USA) vaginal tablets (100 mg) are the newest vaginal natural 
progesterone approved by the FDA. A theoretical advantage 
of Endometrin® compared to the vaginal suppository is that 
the tablets are made to absorb the vaginal secretions and 
disintegrate into an adhesive powder that adheres to the vaginal 
epithelium thus facilitating sustained absorption.34 Theoretically 
the formulation would cause less perineal irritation.34
A study was performed comparing absorption and the side 
effects of perineal irritation from Endometrin® with those of 
a commercially available vaginal progesterone suppository 
available in Europe known as Cyclogest® (Shire Pharmaceuticals 
Ltd., UK). The study found that 200 mg of Endometrin® was 
able to produce the same serum levels after 6 days compared 
to 800 mg Cyclogest®.33 Though there was no significant 
difference in vaginal irritation between the two preparations 
there was a trend for less irritation from Endometrin®.33
Efficacy of Endometrin®
The best test for efficacy of a progesterone preparation is to 
evaluate it under conditions where progesterone is critically 
required for the achievement of a pregnancy. One such 
circumstance is to prepare the endometrium for embryo transfer 
in women with absent or non-functioning ovaries using donor 
oocytes.15,16,35 Adequate late luteal phase histologic changes were 
noted in women whose uteri were prepared with estrogen and 
Endometrin® as the type of progesterone.36,37 The Endometrin® 
was as effective in causing the appropriate secretory changes as 
had been demonstrated for Crinone® and allowed higher serum 
levels of progesterone.36,37 The aforementioned Endometrin® 
studies did not include pregnancy rates.36,37
Endeometrin® for luteal phase 
support in IVF-ET cycles
The efficacy of Endometrin® vaginal tablets used in the 
luteal phases following oocyte retrieval on pregnancy rates 
was compared to Crinone® vaginal gel 8% in a multicenter 
randomized prospective trial.38 Clinical pregnancy rate with 
Endometrin® 100 mg 2 × daily was 40.6% (163/404) vs 
45.3% for Endometrin® 3 × daily vs 43.1% (174/403) with 
Crinone vaginal gel 8% once daily. The comparable ongoing 
pregnancy rates were 38.5% (156/404) 42.5% (171/404), and 
42.0% (170/403), respectively.38
A comparison of Endometrin® vaginal tablets with 
intramuscular progesterone in three studies that were the only 
ones by different research groups found in my search is shown 
in Table 1.23,39,40 There was a significantly higher clinical preg-
nancy rate with IM progesterone versus Endometrin® vaginal 
tablets (42.6% vs 37.0%) (p = 0.015). Only the Khan et al23 
and Mitwally et al39 studies provided miscarriage rates. There 
was no significant difference in ongoing pregnancy rates with 
IM progesterone (47.0%) vs Endometrin® (44.6%).Therapeutics and Clinical Risk Management 2009:5 406
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Summary and conclusions
Endometrin® seems to be an effective method of providing 
progesterone to the endometrium. It is superior to oral 
progesterone tablets in that it is more effective at the endometrial 
level with less side effects. It does not appear to be more 
effective than IM progesterone despite attaining a higher endo-
metrial concentration in the endometrium. However it provides 
a lot fewer side effects. It is equally effective in achieving 
live deliveries compared with Crinone® vaginal gel. It is not 
clear if Endometrin® is less irritating than Crinone® but there 
may be less vaginal accumulation of by-product. Crinone® 
is more convenient however because of the need of only a 
single application. Endometrin® may be less irritating than 
compounded progesterone suppositories at least when the latter 
is not compounded with vitamin E. The use of Endometrin® 
avoids the possibility of batch to batch variation with 
progesterone concentration by compounding pharmacies but the 
compounded vaginal suppositories are generally significantly 
less expensive. At present there are multicenter prospective 
randomized IVF-ET trials using a novel progesterone ring in the 
luteal phase of IVF-ET cycle and the results are being compared 
with “controls” taking Crinone®. The progesterone ring may 
prove to be the best tolerated of all progesterone preparations 
and preliminary data suggest equal efficacy.
The intent of this manuscript was not to provide proof 
that progesterone therapy improves the chances of a live birth 
following IVF-ET or in other circumstances, eg, women with 
infertility, those requiring follicle stimulating drugs or those 
with a history of previous miscarriage. This author is one 
of the physicians who touts the benefits of progesterone.41 
However, the reader should be aware of some of the negative 
views expressed by Drs Malik and Regan.42 This manuscript 
merely reviews the use of this new progesterone preparation 
and mentions some of its advantages over some of the other 
preparations. For those clinicians who believe in the benefits 
of progesterone supplementations in assisted reproductive 
technology, Endometrin® appears to be an efficacious 
preparation with equal efficacy to other vaginal preparations 
in achieving viable pregnancies, with certain advantages over 
other preparations.
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